Moving forward: A mucosal vaccine against group A streptococcus

Expert Review of Vaccines

Volumn 8, Issue 6, 2009, Pages 747-760

  Georgousakis, Melina M ^a   McMillan, David J ^a   Batzloff, Michael R ^a   Sriprakash, Kadaba S ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Mucosal adjuvant; Mucosal delivery; Mucosal immunity; Streptococcus pyogenes; Vaccine

Indexed keywords

STREPTOCOCCUS VACCINE;

BACTERIAL COLONIZATION; IMMUNIZATION; MUCOSAL IMMUNITY; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; SKIN EPITHELIUM; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; HUMANS; IMMUNITY, MUCOSAL; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 67049162199     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.33     Document Type: Review

References (127)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5(11), 685-694 (2005). •• First comprehensive study assessing global disease burden of group A streptococcus. (Pubitemid 41505357)
2. Bisno AL. Primary care: acute pharyngitis. N. Engl. J. Med. 344(3), 205-211 (2001). (Pubitemid 32064142)
3. Breiman RF, Davis JP, Facklam RR et al. Defining the group-A streptococcal toxic shock syndrome - rationale and consensus definition. JAMA 269(3), 390-391 (1993).
4. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13(3), 470 (2000). (Pubitemid 30452618)
5. Fae KC, Oshiro SE, Toubert A, Charron D, Kalil J, Guilherme L. How an autoimmune reaction triggered by molecular mimicry between streptococcal M protein and cardiac tissue proteins leads to heart lesions in rheumatic heart disease. J. Autoimmun. 24(2), 101-109 (2005). (Pubitemid 40501923)
6. Kaplan EL. The group-A streptococcal upper respiratory-tract carrier state - an enigma. J. Pediatrics 97(3), 337-345 (1980). (Pubitemid 11225833)
7. Carapetis JR, Wolff DR, Currie BJ. Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med. J. Aus. 164(3), 146-149 (1996). (Pubitemid 26051106)
8. McDonald MI, Towers RJ, Andrews RM, Benger N, Currie BJ, Carapetis JR. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian Aboriginal communities where acute rheumatic fever is hyperendemic. Clin. Infect. Dis. 43(6), 683-689 (2006). (Pubitemid 44330728)
9. Batzloff MR, Sriprakash KS, Good MF. Vaccine development for group A streptococcus infections and associated diseases. Curr. Drug Targets 5(1), 57-69 (2004). (Pubitemid 38081742)
10. Dale JB, Cleary PP, Fischetti VA, Kaspe DL, Musser JM, Zabriskie JB. Group A and group B streptococcal vaccine development - a round table presentation. In: Streptococci and the Host. Horaud T, Bouvet A, Leclercq R, de Montclos H, Sicard M (Eds). Springer, NY, USA 863-868 (1997). (Pubitemid 27438567)
11. Good MF, Xu HJ, Batzloff M. Adapting immunity with subunit vaccines: case studies with group A streptococcus and malaria. Int. J. Parasitology 32(5), 575-580 (2002). (Pubitemid 34273808)
12. McMillan DJ, Chhatwal GS. Prospects for a group A streptococcal vaccine. Curr. Opin. Mol. Ther. 7(1), 11-16 (2005). (Pubitemid 40287450)
13. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect. Immun. 70(4), 2171-2177 (2002). (Pubitemid 34242220)
14. Batzloff MR, Hayman WA, Davies MR et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8-and diphtheria toxoid-specific antibodies to protection. J. Infect. Dis. 187(10), 1598-1608 (2003). (Pubitemid 36578966)
15. Brandt ER, Hayman WA, Currie B, Pruksakorn S, Good MF. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 15(16), 1805-1812 (1997). (Pubitemid 27449814)
16. Dale JB, Chiang EY, Lederer JW. Recombinant tetravalent group-A streptococcal M-protein vaccine. J. Immunol. 151(4), 2188-2194 (1993). (Pubitemid 23235692)
17. Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin. Diagn. Lab. Immunol. 12(7), 833-836 (2005). (Pubitemid 40993282)
18. Kawabata S, Kunitomo E, Terao Y et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect. Immun. 69(2), 924-930 (2001). (Pubitemid 32109558)
19. McGeary RP, Olive C, Toth I. Lipid and carbohydrate based adjuvant/carriers in immunology. J. Peptide Sci. 9(7), 405-418 (2003). (Pubitemid 36950051)
20. Schulze K, Medina E, Talay SR, Towers RJ, Chhatwal GS, Guzman CA. Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response. Infect. Immun. 69(1), 622-625 (2001). • Identifies the H12 region of SfbI as the domain responsible for inducing a protective immune response at the mucosal surfaces in mice. (Pubitemid 32038372)
21. Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69(7), 4545-4553 (2001). (Pubitemid 32574456)
22. Walker RI. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12(5), 387-400 (1994). (Pubitemid 24107573)
23. Corbett M, Bogers WM, Heeney JL et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc. Natl Acad. Sci. USA 105(6), 2046-2051 (2008).
24. Aziz MA, Midha S, Waheed SM, Bhatnagar R. Oral vaccines: new needs, new possibilities. Bioessays 29(6), 591-604 (2007). (Pubitemid 46903947)
25. Vajdy M, Singh M. The role of adjuvants in the development of mucosal vaccines. Expert Opin. Biol. Ther. 5(7), 953-965 (2005). (Pubitemid 41032851)
26. Yuki Y, Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13(5), 293-310 (2003). (Pubitemid 37082192)
27. Slutter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J. Drug Target. 16(1), 1-17 (2008).
28. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune-system - from fundamental-concepts to vaccine development. Vaccine 10(2), 75-88 (1992).
29. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430 (2001). (Pubitemid 32294678)
30. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat. Rev. Immunol. 3(10), 822-829 (2003). (Pubitemid 37328660)
31. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11(4), S45-S53 (2005). (Pubitemid 40562303)
32. Janeway CT, Walport PM, Capra JD. Immunobiology: The Immune System in Health and Disease. Austin PLE (Ed.). Current Biology Publications, London, UK (1999).
33. Woof JM, Mestecky J. Mucosal immunoglobulins. Immunol. Rev. 206, 64-82 (2005). (Pubitemid 41105163)
34. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int. J. Med. Microbiol. 293(1), 3-15 (2003). (Pubitemid 36534594)
35. Mowat AM, Parker LA, Beacock-Sharp H, Millington OR, Chirdo F. Oral tolerance: overview and historical perspectives. In: Oral Tolerance: New Insights and Prospects for Clinical Application. Weiner HL, Mayer L, Strober W (Eds). Annals of the New York Academy of Sciences, NY, USA 1-8 (2004). (Pubitemid 40298509)
36. Lajeunesse M, Zhang QB, Finn A. Mucosal immunity to infections and its importance in future vaccinology. In: Hot Topics in Infection and Immunity in Children. Finn A, Pollard AJ (Eds). Springer, NY, USA 13-22 (2004).
37. Bessen D, Fischetti VA. Passive acquired mucosal immunity to group-A streptococci by secretory immunoglobulin-A. J. Exp. Med. 167(6), 1945-1950 (1988). • One of the first studies highlighting the role of secretory IgA in the control of group A streptococcal infections. (Pubitemid 18174283)
38. Brandt ER, Hayman WA, Currie B et al. Functional ana lysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int. Immunol. 11(4), 569-576 (1999). (Pubitemid 29179005)
39. Courtney HS, Hasty DL, Dale JB. Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann. Med. 34(2), 77-87 (2002). (Pubitemid 34596845)
40. Simpson WA, Courtney H, Beachey EH. Lipoteichoic acid mediated binding of Streptococcus pyogenes to fibronectin. Fed. Proc. 41(3), 695-1695 (1982).
41. Hasty DL, Ofek I, Courtney HS, Doyle RJ. Multiple adhesins of Streptococci. Infect. Immun. 60(6), 2147-2152 (1992).
42. Ryan PA, Pancholi V, Fischetti VA. Group A streptococci bind to mucin and human pharyngeal cells through sialic acid-containing receptors. Infect. Immun. 69(12), 7402-7412 (2001). (Pubitemid 33086565)
43. Stanislawski L, Simpson WA, Hasty D, Sharon N, Beachey EH, Ofek I. Role of Fibronecting in attachment of Streptococcus pyogenes and Eschericia coli to human cell lines and isoltated oral epithelial cells. Infect. Immun. 48(1), 257-259 (1985). (Pubitemid 15111183)
44. Cue D, Dombek PE, Lam H, Cleary PP. Streptococcus pyogenes serotype M1 encodes multiple pathways for entry into human epithelial cells. Infect. Immun. 66(10), 4593-4601 (1998). (Pubitemid 28453058)
45. Fischetti VA. Streptococcal M-protein - molecular design and biological behavior. Clin. Microbiol. Rev. 2(3), 285-314 (1989). (Pubitemid 19181596)
46. Fischetti VA. Streptococcal M-protein. Sci. Am. 264(6), 58-65 (1991).
47. Batzloff MR, Pandey M, Olive C, Good MF. Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol. Res. 35(3), 233-248 (2006). (Pubitemid 46020725)
48. Ellen RP, Gibbons RJ. M Protein-associated adherence of Streptococcus pyogenes to epithelial surfaces - prerequisite for virulence. Infect. Immun. 5(5), 826-827 (1972).
49. Fenderson PG, Fischetti VA, Cunningham MW. Tropomyosin shares immunologic epitopes with group A streptococcal M proteins. J. Immunol. 142(7), 2475-2481 (1989). (Pubitemid 19098264)
50. Gubbe K, Misselwitz R, Welfle K, Reichardt W, Schmidt KH, Welfle H. C repeats of the streptococcal M1 protein achieve the human serum albumin binding ability by flanking regions which stabilize the coiled-coil conformation. Biochemistry 36(26), 8107-8113 (1997). (Pubitemid 27284188)
51. Oliver M, Feito M, Sanchez A et al. Membrane cofactor protein (CD46) binding to clinical isolates of Streptococcus pyogenes: binding to M type 18 strains is independent of Emm or Enn proteins. Int. J. Antimicrob. Agents 29, S18-S19 (2007).
52. Courtney HS, Ofek I, Hasty DL. M protein mediated adhesion of M type 24 Streptococcus pyogenes stimulates release of interleukin-6 by HEp-2 tissue culture cells. FEMS Microbiol. Lett. 151(1), 65-70 (1997). (Pubitemid 27286268)
53. Schmidt KH, Mann K, Cooney J, Kohler W. Multiple binding of type-3 Streptococcal M-protein to human fibrinogen, albumin and fibronectin. FEMS Immunol. Med. Microbiol. 7(2), 135-144 (1993). (Pubitemid 23255973)
54. Tylewska SK, Fischetti VA, Gibbons RJ. Binding selectivity of Streptococcus pyogenes and M-protein to epithelial-cells differs from that of lipoteichoic acid. Curr. Microbiol. 16(4), 209-216 (1988). (Pubitemid 18069169)
55. Caparon MG, Stephens DS, Olsen A, Scott JR. Role of M-protein in adherence of group-A streptococci. Infect. Immun. 59(5), 1811-1817 (1991).
56. Kreikemeyer B, Klenk M, Podbielski A. The intracellular status of Streptococcus pyogenes: role of extracellular matrix-binding proteins and their regulation. Int. J. Med. Microbiol. 294(2-3), 177-188 (2004). (Pubitemid 39281048)
57. Schwarz-Linek U, Hook M, Potts JR. The molecular basis of fibronectin-mediated bacterial adherence to host cells. Mol. Microbiol. 52(3), 631-641 (2004). (Pubitemid 38621735)
58. Edwards ML, Fagan PK, Currie BJ, Sriprakash KS. The fibronectin-binding capacity and host cell adherence of Streptococcus pyogenes strains are discordant with each other. Microbes Infect. 6(13), 1156-1162 (2004). (Pubitemid 39370083)
59. Jaffe J, Natanson-Yaron S, Caparon MG, Hanski E. Protein F2, a novel fibronectin-binding protein from Streptococcus pyogenes, possesses two binding domains. Mol. Microbiol. 21(2), 373-384 (1996). (Pubitemid 26291542)
60. Courtney HS, Dale JB, Hasty DL. Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells. Infect. Immun. 64(7), 2415-2419 (1996). (Pubitemid 26226798)
61. Oehmcke S, Podbielski A, Kreikemeyer B. Function of the fibronectin-binding serum opacity factor of Streptococcus pyogenes in adherence to epithelial cells. Infect. Immun. 72(7), 4302-4308 (2004). (Pubitemid 38821950)
62. Kreikemeyer B, Martin DR, Chhatwal GS. SfbII protein, a fibronectin binding surface protein of group A streptococci, is a serum opacity factor with high serotype-specific apolipoproteinase activity. FEMS Microbiol. Lett. 178(2), 305-311 (1999). (Pubitemid 29412901)
63. Edwards ML, Fagan PK, Towers RJ, Currie BJ, Sriprakash KS. Inhibition of Streptococcus pyogenes adherence to HaCaT cells by a peptide corresponding to the streptococcal fibronectin-binding protein, SfbI, is strain dependent. Microbes Infect. 6(10), 926-928 (2004). (Pubitemid 39061214)
64. Vanheyningen T, Fogg G, Yates D, Hanski E, Caparon M. Adherence and fibronectin-binding are environmentally regulated in the group-A streptococci. Mol. Microbiol. 9(6), 1213-1222 (1993). (Pubitemid 23286252)
65. Okada N, Pentland AP, Falk P, Caparon MG. M-protein and protein-F act as important determinants of cell-specific tropism of Streptococcus pyogenes in skin tissue. J. Clin. Invest. 94(3), 965-977 (1994).
66. Abbot EL, Smith WD, Siou GPS et al. Pili mediate specific adhesion of Streptococcus pyogenes to human tonsil and skin. Cell. Microbiol. 9(7), 1822-1833 (2007). •• First study describing a role for group A streptococcal pili in cell adhesion. The exact mechanisms behind this adhesion are yet to be described.
67. Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. Laryngoscope 107(5), 640-647 (1997). • Describes the presence and survival of group A streptococcus within respiratory epithelial cells from infected individuals. (Pubitemid 27200638)
68. Lapenta D, Rubens C, Chi E, Cleary PP. Group-A streptococci efficiently invade human respiratory epithelial-cells. Proc. Natl Acad. Sci. USA 91(25), 12115-12119 (1994). • One of the first studies describing the ability of group A streptococcus to invade human cells.
69. Talay SR, Zock A, Rohde M et al. Co-operative binding of human fibronectin to SfbI protein triggers streptococcal invasion into respiratory epithelial cells. Cell. Microbiol. 2(6), 521-535 (2000). (Pubitemid 32049322)
70. Molinari G, Talay S, Valentin-Weigand P, Rohde M, Chhatwal G. The fibronectin-binding protein of Streptococcus pyogenes, SfbI, is involved in the internalization of group A streptococci by epithelial cells. Infect. Immun. 65(4), 1357-1363 (1997). (Pubitemid 27146625)
71. Staali L, Morgelin M, Bjorck L, Tapper H. Streptococcus pyogenes expressing M and M-like surface proteins are phagocytosed but survive inside human neutrophils. Cell. Microbiol. 5(4), 253-265 (2003). (Pubitemid 36511572)
72. Fluckiger U, Jones KF, Fischetti VA. Immunoglobulins to group A streptococcal surface molecules decrease adherence to and invasion of human pharyngeal cells. Infect. Immun. 66(3), 974-979 (1998). (Pubitemid 28101135)
73. Cue D, Southern SO, Southern PJ et al. A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin a 5 b 1-fibronectin-M1 protein complexes. Proc. Natl Acad. Sci. USA 97(6), 2858-2863 (2000). (Pubitemid 30159262)
74. Talay SR, Valentinweigand P, Timmis KN, Chhatwal GS. Domain-structure and conserved epitopes of Sfb protein, the fibronectin-binding adhesin of Streptococcus pyogenes. Mol. Microbiol. 13(3), 531-539 (1994). (Pubitemid 124000202)
75. Wang BN, Yurecko RS, Dedhar S, Cleary PP. Integrin-linked kinase is an essential link between integrins and uptake of bacterial pathogens by epithelial cells. Cell. Microbiol. 8(2), 257-266 (2006).
76. Marouni MJ, Barzilai A, Keller N, Rubinstein E, Sela S. Intracellular survival of persistent group A streptococci in cultured epithelial cells. Int. J. Med. Microbiol. 294(1), 27-33 (2004). (Pubitemid 38915610)
77. Guzman CA, Talay SR, Molinari G, Medina E, Chhatwal GS. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin binding protein SfbI. J. Infect. Dis. 179(4), 901-906 (1999). (Pubitemid 29159335)
78. Park HS, Francis KP, Yu J, Cleary PP. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. J. Immunol. 171(5), 2532-2537 (2003). •• Describes an interaction between group A streptococcus and murine M cells and demonstrates the role of M cells as a portal for bacterial dissemination using bioluminescent recombinant bacteria.
79. Park HS, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect. Immun. 73(12), 7878-7886 (2005).
80. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev. Vaccines 7(1), 7-10 (2008).
81. Facklam RF, Martin DR, Lovgren M et al. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. Clin. Infect. Dis. 34(1), 28-38 (2002). (Pubitemid 33152662)
82. Krisher K, Cunningham MW. Myosin - a link between streptococci and heart. Science 227(4685), 413-415 (1985). (Pubitemid 15153497)
83. Massell BF, Honikman LH, Amezcua J. Rhuematic fever following streptococcal vaccination. Report of three cases. JAMA 207, 1115-1119 (1969).
84. Tagliabue A, Rappudi R. Vaccine adjuvants: the dream becomes real. Hum. Vaccine 4(5), 347-349 (2008).
85. Spangler BD. Structure and function of cholera-toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56(4), 622-647 (1992).
86. Verdonck F, Snoeck V, Goddeeris BM, Cox E. Cholera toxin improves the F4(K88)-specific immune response following oral immunization of pigs with recombinant FaeG. Vet. Immunol. Immunopathol. 103(1-2), 21-29 (2005). (Pubitemid 40038219)
87. Pizza M, Giuliani MM, Fontana MR et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19(17-19), 2534-2541 (2001). (Pubitemid 32234269)
88. Bessen D, Fischetti VA. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M-protein on mucosal colonization by group-A streptococci. Infect. Immun. 56(10), 2666-2672 (1988). • One of the first studies demonstrating that peptide vaccines delivered intranasally with adjuvant cholera toxin B subunit can reduce mucosal colonization of group A streptococcus in mice. (Pubitemid 18231572)
89. Bronze MS, Courtney HS, Dale JB. Epitopes of group-A streptococcal M-protein that evoke cross-protective local immune-responses. J. Immunol. 148(3), 888-893 (1992).
90. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int. Immunol. 9(11), 1723-1733 (1997). •• First paper describing the development of peptide vaccine derived from the conserved M protein of group A streptococcus. (Pubitemid 27494135)
91. Brandt ER, Hayman WA, Currie B et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 89(3), 331-337 (1996). (Pubitemid 26380072)
92. Olive C, Clair T, Yarwood P, Good MR. Protection of mice from group A streptococcal infection by intranasal immunization with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 20(21-22), 2816-2825 (2002). (Pubitemid 34597142)
93. McArthur J, Medina E, Mueller A et al. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model. Infect. Immun. 72(12), 7342-7345 (2004). •• Describes that the group A streptococcal virulence factor SfbI, which shows promise in the mucosal model, is not protective against systemic group A streptococcal challenge. (Pubitemid 39552411)
94. McArthur J, Schulze K, Chin J et al. Immune responses of a liposome/ISCOM vaccine adjuvant against streptococcal fibronectin binding protein 1 (Sfb1) in mice. Indian J. Med. Res. 119, 115-120 (2004). (Pubitemid 39004459)
95. Schulze K, Guzman CA. Identification of the domains of the fibronectin-binding protein I of Streptococcus pyogenes responsible for adjuvanticity. FEMS Immunol. Med. Microbiol. 37(2-3), 173-177 (2003). (Pubitemid 36776500)
96. Schulze K, Medina E, Guzman CA. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain. Vaccine 24(9), 1446-1450 (2006). (Pubitemid 43222057)
97. Courtney HS, Hasty DL, Dale JB. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect. Immun. 71(9), 5097-5103 (2003). (Pubitemid 37070752)
98. Wexler DE, Chenoweth DE, Cleary PP. Mechanism of action of the group-A streptococcal C5a inactivator. Proc. Natl Acad. Sci. USA 82(23), 8144-8148 (1985).
99. Ji YD, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A streptococcus. Infect. Immun. 65(6), 2080-2087 (1997). (Pubitemid 27237281)
100. Cleary PP, Matsuka YV, Huynh T, Lam H, Olmsted SB. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine 22(31-32), 4332-4341 (2004). (Pubitemid 39330358)
101. Chmouryguina I, Suvorov A, Ferrieri P, Cleary PP. Conservation of the C5a peptidase genes in group A and B streptococci. Infect. Immun. 64(7), 2387-2390 (1996). (Pubitemid 26226794)
102. Kersten GFA, Crommelin DJA. Liposomes and iscoms as vaccine formulations. Biochimica Biophysica Acta 1241(2), 117-138 (1995).
103. Owais M, Masood AK, Agrewala JN, Bisht D, Gupta CM. Use of liposomes as an immunopotentiating delivery system: in perspective of vaccine development. Scandinavian J. Immunol. 54(1-2), 125-132 (2001). (Pubitemid 32592337)
104. Jepson MA, Clark MA, Hirst BH. M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv. Drug Deliv. Rev. 56(4), 511-525 (2004). (Pubitemid 38210420)
105. Chin J, SanGil F, Novak M et al. Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants. J. Biotechnol. 44(1-3), 13-19 (1996). (Pubitemid 26056560)
106. Hall MA, Stroop SD, Hu MC et al. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect. Immun. 72(5), 2507-2512 (2004). •• Comprehensive study that compares the immunogenicity of a multivalent vaccine antigen when delivered to mice intranasally in conjunction with multiple mucosal adjuvants. (Pubitemid 38542375)
107. Dale JB. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine 17(2), 193-200 (1999). (Pubitemid 28494119)
108. Batzloff MR, Yan H, Davies MR et al. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group A streptococcus. J. Infect. Dis. 192(8), 1450-1455 (2005). (Pubitemid 41401160)
109. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 408(6813), 740-745 (2000). (Pubitemid 32015992)
110. Tsan MF, Gao BC. Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J. Endotoxin Res. 13(1), 6-14 (2007).
111. Batzloff MR, Hartas J, Zeng WG, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J. Infect. Dis. 194(3), 325-330 (2006). (Pubitemid 44116974)
112. Jackson DC, Lau YF, Le T et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 101(43), 15440-15445 (2004). (Pubitemid 39441560)
113. Olive C, Batzloff M, Horvath A et al. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect. Immun. 71(5), 2373-2383 (2003). (Pubitemid 36519848)
114. Toth I, Danton M, Flinn N, Gibbons WA. A combined adjuvant and carrier system for enhancing synthetic peptides immunogenicity utilizing lipidic amino-acids. Tetrahedron Lett. 34(24), 3925-3928 (1993). (Pubitemid 23179470)
115. Olive C, Sun HK, Ho MF et al. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J. Infect. Dis. 194(3), 316-324 (2006). (Pubitemid 44116973)
116. Poirier TP, Kehoe MA, Beachey EH. Protective immunity evoked by oral-administration of attenuated aroa Salmonella typhimurium expressing cloned Streptococcal M-protein. J. Exp. Med. 168(1), 25-32 (1988). (Pubitemid 18195131)
117. Fischetti VA, Hodges WM, Hruby DE. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science 244(4911), 1487-1490 (1989). (Pubitemid 19171685)
118. Stalhammar-Carlemalm M, Waldemarsson J, Johnsson E, Areschoug T, Lindahl G. Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine. Cell Host Microbe 2(6), 427-434 (2007). (Pubitemid 350215324)
119. Mannam P, Jones KF, Geller BL. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect. Immun. 72(6), 3444-3450 (2004). •• Proof-of-principle study highlighting the potential of commensal bacteria as a method for mucosal delivery of subunit-based vaccines against group A streptococcus. (Pubitemid 38697770)
120. Pozzi G, Oggioni MR, Manganelli R, Fischetti VA. Expression of M6 protein gene of Streptococcus pyogenes in Streptococcus gordonii after chromosomal integration and transcriptional fusion. Res. Microbiol. 143(5), 449-457 (1992).
121. Bolken TC, Franke CA, Jones KF et al. Analysis of factors affecting surface expression and immunogenicity of recombinant proteins expressed by Gram-positive commensal vectors. Infect. Immun. 70(5), 2487-2491 (2002). (Pubitemid 34408391)
122. Byrd CM, Bolken TC, Jones KF et al. Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors. Vaccine 20(17-18), 2197-2205 (2002). (Pubitemid 34497028)
123. Kotloff KL, Wasserman SS, Kevin FJ et al. Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect. Immun. 73(4), 2360-2366 (2005). (Pubitemid 40470839)
124. Pruksakorn S, Galbraith A, Houghten RA, Good MF. Conserved T-cell and B-cell epitopes on the m-protein of group-A streptococci - induction of bactericidal antibodies. J. Immunol. 149(8), 2729-2735 (1992).
125. Tart AH, Walker MJ, Musser JM. New understanding of the group A streptococcus pathogenesis cycle. Trends Microbiol. 15(7), 318-325 (2007). (Pubitemid 47017709)
126. Sumby P, Tart AH, Musser JM. A nonhuman primate model of acute group A streptococcus pharygnitis. Methods Mol. Biol. 431, 255-267 (2008).
127. ID Biomedical Corporation Technologies: Nasal Vaccine Delivery and Adjuvant Systems www.idbiomedical.com/technologies-prote.html (Accessed 4th May 2005)